PDF(Pubmed)
Abstract：
Lobeglitazone is a newer oral hypoglycemic agent that has been tested in type 2 diabetes mellitus (T2DM). We aim to conduct a narrative review to find out the therapeutic benefits of lobeglitazone in patients with T2DM. We scientifically searched the electronic database of PubMed from inception until September 12, 2023, using Medical Subject Heading (MeSH) keywords. Additionally, we searched for pre-clinical trials related to lobeglitazone. We retrieved all available results of phase 1 to phase 3 studies of lobeglitazone in T2DM. Subsequently, we reviewed the results narratively. Three double-blind, randomized, placebo-controlled studies and a phase 3 trial of lobeglitazone showed that 0.5 mg daily dose exhibits effective therapeutic activity in glycemic, lipid, and hepatic control, and is also used as a secondary treatment in non-alcoholic fatty liver disease. Lobeglitazone exhibits as much antidiabetic activity as other thiazolidinediones such as pioglitazone and rosiglitazone. Side effects of lobeglitazone included peripheral edema, weight gain, and bone mineral density, which did not require hospitalization for these effects. This article highlights the pharmacological, pre-clinical, clinical, and safety pharmacology of novel thiazolidinedione lobeglitazone.
摘要：
洛格列酮是一种较新的口服降血糖药，已在2型糖尿病（T2DM）中进行了测试。我们的目标是进行叙述性审查，以了解2型糖尿病患者的治疗益处。从成立到2023年9月12日，我们使用医学主题标题（MeSH）关键字科学地搜索了PubMed的电子数据库。此外,我们搜索了与洛格列酮相关的临床前试验.我们检索了2型糖尿病患者的1期至3期研究的所有可用结果。随后，我们叙述了结果。三个双盲，随机化，安慰剂对照研究和洛格列酮的3期试验表明，0.5毫克每日剂量在血糖方面表现出有效的治疗活性，脂质，和肝脏控制，也可用作非酒精性脂肪性肝病的二级治疗。与其它噻唑烷二酮类如吡格列酮和罗格列酮一样,洛格列酮显示出同样多的抗糖尿病活性。洛格列酮的副作用包括外周水肿，体重增加,和骨密度，这些影响不需要住院治疗。这篇文章重点介绍了药理学，临床前，临床,以及新型噻唑烷二酮的安全药理学。
